NTRA vs TMO
Natera, Inc. and Thermo Fisher Scientific, both Healthcare
Thermo Fisher Scientific is the larger company at $173B against $37B. Over the past year NTRA returned +121% against +37% for TMO. The RyuScore puts TMO ahead, 50 against 18 out of 100.
| Figure | NTRA | TMO |
|---|---|---|
| Last close | $401 | $658 |
| Market cap | $37B | $173B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 35.4 |
| Dividend yield | n/a | 0.3% |
| 1-year return | +121% | +37% |
| 5-year return | +234% | +19% |
| RyuScoresector-relative, 1–10 | 18/100 | 50/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Natera, Inc.
Revenue of $753M in Q2 2026, net income null. Its largest reported line is United States, 98% of the disclosed total.
Thermo Fisher Scientific
Revenue of $12B in Q2 2026, net income $1.7B. Its largest reported line is Life Sciences Solutions, 38% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.